Skip to main content
Premium Trial:

Request an Annual Quote

GreenLight Biosciences Raises $50M in Private Financing Round

NEW YORK (GenomeWeb) — GreenLight Biosciences announced today that it has raised $50 million in an oversubscribed private financing round.

The round was led by S2G Ventures, Baird Capital, and Blue I/O. Other investors included Continental Grain Company, Tao Capital Partners, and Alexandria Venture Investments.

GreenLight is using its cell-free bioprocessing platform to develop RNA-based agricultural products such as double-stranded RNA biopesticides for high-value crops. The Medford, Massachusetts-based firm said it will use the new funding to continue these efforts and to expand into new markets such as human and animal therapeutics.

"We're now at a price point and purity level that opens up a host of markets and applications to an RNA-based solution that was previously limited to the highest-value human therapeutic markets," Matthew Walker, managing director at S2G Ventures, said in a statement. "The GreenLight technology and products have the potential to bring about a new modality in human, animal, and plant health, providing highly effective, targeted solutions that compete with or outperform traditional chemical treatments in terms of cost, efficacy, and off-target impacts."

GreenLight also said it closed an $18 million Series D round in September 2017.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.